

1 **Increased intracellular action of MP1102 and NZ2114 against *Staphylococcus aureus* in vitro and**
2 ***in vivo***

3 **Xiao Wang^{1,2*}, Xiumin Wang^{1,2**}, Da Teng^{1,2*}, Ruoyu Mao^{1,2}, Ya Hao^{1,2}, Na Yang^{1,2}, Zhanzhan Li^{1,2},**
4 **Jianhua Wang^{1,2**}**

5 **¹ Key Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing 100081, P. R. China. ²**
6 **Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural Sciences,**
7 **Beijing 100081, P. R. China. * Equal contributors into this paper. ** Correspondence and requests**
8 **for materials should be addressed to X.M.W. (email: wangxiumin@caas.cn) and J.H.W. (email:**
9 **wangjianhua@caas.cn)**

10

11 **SUPPORTING INFORMATION**

12 **Supplementary 1: Materials and Methods**

13 **Antimicrobial susceptibility testing of *S. aureus*.** Antimicrobial susceptibility testing of *S. aureus*
14 (ATCC43300 and CVCC546) was performed by Kirby Bauer disc diffusion method according to the
15 standards procedures recommended by Clinical Laboratory Standards Institute (CLSI 2012)^{1,2}. The used
16 22 antibiotics included: 1) aminoglycosides (amikacin, neomycin, gentamicin, kanamycin, and
17 streptomycin), 2) quinolones (ciprofloxacin, norfloxacin), 3) sulfonamides (sulfisoxazole), 4)
18 tetracyclines (tetracycline), 5) polypeptides (bacitracin and polymyxin B), 6) penicillins (penicillin,
19 amoxicillin, ampicillin, oxacillin), 7) lincosamides (lincomycin), 8) macrolides (erythromycin and
20 azithromycin), 9) amphenicols (chloramphenicol), 10) glycopeptides (vancomycin), and 11)
21 cephalosporins (cefazolin and cefotaxime) (Qianshun Bio-tech, Beijing).

22 **SCC*mec* and *spa* typing of *S. aureus*.** For rapid DNA extraction, one to five bacterial colonies were

23 suspended in 50 µl of sterile distilled water and heated at 100°C for 10 min. Then the solution was frozen
24 in -80°C for 30 min and heated at 100°C for 10 min. After centrifugation at 5000 rpm/min for 2 min. A
25 total of 2 µl of the supernatant was used as a template in a 50-µl PCR. The SCC*mec* and x region of the
26 *spa* gene was amplified by PCR with primers in Supplementary Table 1³⁻⁵. The x region of the *spa* genes
27 was sequenced by Sangon Biotech (Shanghai, China) and the types were determined with the database
28 accessible via <http://spa.ridom.de/spatypes.shtml>.

29 **Growth curves of *S. aureus*.** The *S. aureus* ATCC25923, ATCC43300 and CVCC546 strains were
30 used to evaluate growth rate in Mueller – Hinton broth (MHB)⁶. Briefly, overnight cultures in MHB was
31 inoculated into 50 ml of fresh MHB (with the inoculum size of 1% (v/v))⁷. All flasks were incubated at
32 37°C for 15 h with shaking (250 rpm). Aliquots (2 ml) were taken out per hour to determine the culture
33 turbidity at 600 nm in a TU-1810 ultraviolet visible spectrophotometer. It was performed for three times.

34 **FITC-labeled peptides.** The FITC-labeled peptides were carried out in ChinaPeptides Co., Ltd.
35 (Shanghai, China) as previously described⁸. The peptides (MP1102 or NZ2114) were dissolved in 0.2 M
36 PBS (pH 8.4) containing 1.1 equivalent of FITC. The mixture was stirred at room temperature for 12 h
37 to complete the reaction. The reaction product was then dialyzed in dialysis tubing MD18 (with a
38 molecular weight cut-off 2.0 kDa) at 4°C for 48 h with an exchange of ddH₂O per 12 h to remove free
39 FITC. The fluorescence intensity of FITC in dialyzed ddH₂O was monitored to assure the complete
40 removal of free FITC. Finally, the product was lyophilized in a freezer dryer for 36 h. The procedure was
41 kept away from light.

42 **References:**

43 [1] Kahsay, A., Mihret, A., Abebe, T., Andualem, T. Isolation and antimicrobial susceptibility pattern of
44 *Staphylococcus aureus* in patients with surgical site infection at Debre Markos Referral Hospital, Amhara

- 45 Region, Ethiopia. *Arch Public Health* **72**, 16 (2014).
- 46 [2] Wikler, M. A., *et al.* Performance standards for antimicrobial sensitivity testing: seventeenth
47 informational supplement. CLSI. **26**, 1–177 (2007).
- 48 [3] Zhang, K., McClure, J. A., Elsayed, S., Louie, T., Conly, J. M. Novel multiplex PCR assay for
49 characterization and concomitant subtyping of staphylococcal cassette chromosome *mec* types I to V in
50 methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* **43**, 5026–5033 (2005).
- 51 [4] Rong, D., Wu, Q., Xu, M., Zhang, J., Yu, S. Prevalence, virulence genes, antimicrobial susceptibility,
52 and genetic diversity of *Staphylococcus aureus* from retail aquatic products in China. *Front Microbiol* **8**,
53 714 (2017).
- 54 [5] Strommenger, B., *et al.* *spa* Typing of *Staphylococcus aureus* as a frontline tool in epidemiological
55 typing. *J Clin Microbiol* **46**, 574–81 (2008).
- 56 [6] Diarra, M. S., Petitclerc, D., Lacasse, P. Response of *Staphylococcus aureus* isolates from bovine
57 mastitis to exogenous iron sources. *J Dairy Sci* **85**, 2141–2148 (2002).
- 58 [7] Buchanan, R. L., *et al.* Response surface models for the effects of temperature, pH, sodium chloride,
59 and sodium nitrite on the aerobic and anaerobic growth of *Staphylococcus aureus* 196e1. *J Food Safety*
60 **13**:159–175 (1993).
- 61 [8] Sun, X. X., *et al.* Fluorescence characterization of the thermal stability of collagen mimic peptides.
62 *Chinese Chem Lett* **28**, 963–967 (2017).

63

64 **Supplementary 2: Tables**

65

66

Table 1 Primers used in SCC*mec* and *spa* typing of *S. aureus*

Name	Primer (5'→3')	Amplicon size (bp)	Reference
SCC<i>mec</i> type			
SCC <i>mec</i> I-F	GCTTTAAAGAGTGTCGTTACAGG	613	3, 4
SCC <i>mec</i> I -R	GTTCTCTCATAGTATGACGTCC		
SCC <i>mec</i> II -F	CGTTGAAGATGATGAAGCG	398	
SCC <i>mec</i> II -R	CGAAATCAATGGTTAATGGACC		
SCC <i>mec</i> III-F	CCATATTGTGTACGATGCG	280	
SCC <i>mec</i> III-R	CCTTAGTTGTCGTAACAGATCG		
SCC <i>mec</i> IVa-F	GCCTTATTCGAAGAAACCG	776	
SCC <i>mec</i> IVa-R	CTACTCTTCTGAAAAGCGTCG		
SCC <i>mec</i> IVb-F	TCTGGAATTACTTCAGCTGC	493	
SCC <i>mec</i> IVb-R	AAACAATATTGCTCTCCCTC		
SCC <i>mec</i> IVc-F	ACAATATTTGTATTATCGGAGAGC	200	
SCC <i>mec</i> IVc-R	TTGGTATGAGGTATTGCTGG		
SCC <i>mec</i> IVd-F	CTCAAATACGGACCCCAATACA	881	
SCC <i>mec</i> IVd-R	TGCTCCAGTAATTGCTAAAG		
SCC <i>mec</i> V -F	GAACATTGTTACTTAAATGAGCG	325	
SCC <i>mec</i> V -R	TGAAAGTTGTACCCTTGACACC		
<i>mecA</i> gene			
<i>mecA</i> -F	GTGAAGATATACCAAGTGATT	147	3
<i>mecA</i> -R	ATGCGCTATAGATTGAAAGGAT		
<i>mecI</i> -F	CCCTTTTTATACAATCTCGTT	146	
<i>mecI</i> -R	ATATCATCTGCAGAATGGG		
<i>Spa</i> type			
<i>Spa</i> -x-F	TAAAGACGATCCTTCGGTGAGC	-	5
<i>Spa</i> -x-R	CAGCAGTAGTGCCGTTTGCTT		

67

68 -: no data. The primers were synthesized by Sangon Biotech (Shanghai, China).

69

70

Table 2 Antimicrobial susceptibility patterns of *S. aureus* ATCC43300 and CVCC546

71

Antibiotics	<i>S. aureus</i> ATCC43300	<i>S. aureus</i> CVCC546
Vancomycin	S	S
Lincomycin	R	I
Amoxicillin	R	S
Ciprofloxacin	S	S
Amikacin	R	S
Ampicillin	R	S
Oxacillin	R	S
Erythromycin	R	I
Tetracycline	I	R
Bacitracin	I	R
Norfloxacin	S	S
Polymyxin B	R	R
Sulfisoxazole	R	R
Neomycin	R	I
Azithromycin	R	S
Kanamycin	R	I
Streptomycin	I	S
Cefotaxime	I	I
Gentamicin	R	S
Chloramphenicol	S	S
Cefazolin	S	S
Penicillin	R	I

87

R: resistant; I: Intermediate; S: susceptible.

88

89

Table 3 Sources, types and susceptibilities of different *S. aureus* strains

90

<i>S. aureus</i>	Source	SCCmec type	Spa type	Antibiotic resistance profile	Biosafety level
Methicillin-susceptible ATCC25923	Clinical isolate	-	-	-	II
Methicillin-resistant ATCC43300	Clinical isolate	II	t007	Methicillin, oxacillin ^a	II
Highly virulent CVCC546	Isolation from a pig in Beijing, China	-	t034	Tetracycline, bacitracin, polymyxin B and sulfisoxazole ^b	III

91 -: negative. a: the ATCC website. b: in this study.

92

93 **Table 4** Effect of cathepsin B on the MICs of MP1102, NZ2114 against *S. aureus* resistant ATCC43300

94


	MIC ($\mu\text{g/ml}$)	
	Buffer + AMP	Buffer + cathepsin B + AMP
MP1102	0.25	0.25
NZ2114	0.5	0.5

95

96

97

98



B

S. aureus ATCC43300

TAATTAAGACGATCCTTCGGTGAGCAAAGAAATTTAGCAGAAGCTAAAAAGCTAAA
 CGATGCTCAAGCACAAAAGAGGAAGACAACAACAAGCCTGGCAAAGAAGACAACA
 ACAAGCCTGGTAAAGAAGACGGCAACAAACCTGGTAAAGAAGACGGCAACAAACCT
 GGTAAAGAAGACGGCAACAAACCTGGTAAAGAAGACGGCAACAAACCTGGTAAAGA
 AGACAACAAAAACCTGGCAAAGAAGATGGCAACAAACCTGGTAAAGAAGACGGCA
 ACAAGCCTGGTAAAGAAGACGGCAACGGAGTACATGTCGTAAACCTGGTGATACAGT
 AAATGACATTGCAAAAGCAAACGGCACTACTGCTG
 t007,15-12-16-16-16-16-02-25-17

S. aureus CVCC546

TAAAGACGATCCTTCGGTGAGCAAAGAAATTTAGCAGAAGCTAAAAAGCTAAACGAT
 GCTCAAGCACAAAAGAGGAAGACAACAACAAGCCTGGTAAAGAAGACGGCAACAA
 ACCTGGTAAAGAAGACAACAAAAACCTGGCAAAGAAGATGGCAACAAACCTGGTA
 AAGAAGACAACAAAAACCTGGCAAAGAAGATGGCAACAAACCTGGTAAAGAAGAC
 AACAAAAACCTGGTAAAGAAGATGGCAACAAGCCTGGTAAAGAAGATGGCAACAA
 ACCTGGTAAAGAAGACGGCAACGGAAATACATGTCGTAAACCTGGTGATACAGTAAAT
 GACATTGCAAAAGCAAACGGCACTACTGCTG
 t034,08-16-02-25-02-25-34-24-25

100


101

Fig. S1

102

Figure 1 PCR assay identifies SCCmec and spa types and subtypes and simultaneously detects the

103 methicillin resistance (*mecA* gene). **(A)** Gel electrophoresis. M: DNA Marker II; 1-12: *S. aureus*
104 ATCC25923; 13-24: *S. aureus* ATCC43300; 25-36: *S. aureus* CVCC546. 1, 13, 25: SCC*mec* I; 2, 14, 26:
105 SCC*mec* II; 3, 15, 27: SCC*mec* III; 4, 16, 28: SCC*mec* IVe; 5, 17, 29: SCC*mec* IVe; 6, 18, 30:
106 SCC*mec* IVc; 7, 19, 31: SCC*mec* IVe; 8, 20, 32: SCC*mec* V; 9, 21, 33: spa-x-1; 10, 22, 34: spa-x-2;
107 11, 23, 35: *mecA*; 12, 24, 36: *mec* I. **(B)** The x region of the *spa* gene sequence.
108




111 **Figure 2** Growth curves of *S. aureus* ATCC25923 (A), ATCC43300 (B) and CVCC546 (C) at pH 5.0

112 and pH 7.3.

113

114



115

116

Fig. S3


117 **Figure 3** Viability of RAW 264.7 cells incubated with NZ2114 and MP1102 for 24 h. RAW 264.7 cells

118 were incubated with 1-256 µg/ml for 24 h and subsequently cell viability was determined using the MTT

119 assay. Results are means \pm S.D. for three experiments.

120

121



122

Fig. S4

123 **Figure 4** Effect of MP1102 and NZ2114 on the cell membrane of RAW 264.7 cells. Cells were incubated

124 with different concentrations of MP1102 and NZ2114 for 24 h prior to staining with 5 $\mu\text{g/ml}$ PI at 37°C

125 for 10 min. PI fluorescence in RAW 264.7 cells was measured by flow cytometry. Red line: control;

126 black line: 25 $\mu\text{g/ml}$ MP1102; green line: 250 $\mu\text{g/ml}$ MP1102; orange line: 25 $\mu\text{g/ml}$ NZ2114; green line:

127 250 $\mu\text{g/ml}$ NZ2114.

128